Biocompatible Delivery System for Metformin: Characterization, Radiolabeling and in Vitro Studies

Basit Öğe Kaydı
dc.contributor.authorAydin, Burcu
dc.contributor.authorUcar, Eser
dc.contributor.authorTekin, Volkan
dc.contributor.authorIchedef, Cigdem
dc.contributor.authorTeksoz, Serap
dc.date.accessioned2020-12-01T12:05:06Z
dc.date.available2020-12-01T12:05:06Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: in recent years, the uses of nanotechnology in medicine have an increasing potential as an effective nanocarrier system. These systems are improved with the purpose of maximizing therapeutic activity and minimizing undesirable side-effects. Moreover, radiolabeled nanoparticles can be used as agents for diagnosis and therapeutic purposes in clinical applications. They have three main components: the core, the targeting biomolecule, and the radionuclide. Objective: It is aimed to synthesize Metformin (MET) loaded Solid Lipid Nanoparticles (MET-SLN) and radiolabeled with technetium-99m tricarbonyl core. Methods: the structure of synthesized nanoparticles was characterized by Fourier Transform Infrared Spectroscopy (FTIR). the particle size and morphology of nanoparticles were examined by Dynamic Light Scattering (DLS), and Scanning Electron Microscope (SEM). Quality control studies of radiolabeled MET-SLN [Tc-99m(CO)(3)-MET-SLN] were performed by High-Performance Liquid Radiochromatography (HPLRC) and Thin Layer Radiochromatography (TLRC). Results: the radiolabeling yield of [Tc-99m(CO)(3)-MET-SLN] was found to be 88%. in vitro studies have been performed on cancer lines(MCF7, MDA-MD-231 breast, and HEPG2 liver cancer cells) to determine the biological behavior of Tc-99m(CO)3-MET-SLNs. Conclusion: the results showed that higher uptake values were observed on estrogen-positive MCF7 breast cancer cell line according to estrogen negative MDA-MB-231 breast cancer and HEPG2 liver cancer cell lines.en_US
dc.description.sponsorshipScientific Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [113S369]en_US
dc.description.sponsorshipThis study was subsidized by the Scientific Technological Research Council of Turkey (TUBITAK, Project no: 113S369).en_US
dc.identifier.doi10.2174/1871520620666200423081235en_US
dc.identifier.endpage1634en_US
dc.identifier.issn1871-5206
dc.identifier.issn1875-5992
dc.identifier.issue13en_US
dc.identifier.pmid32324524en_US
dc.identifier.scopus2-s2.0-85088953120en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1626en_US
dc.identifier.urihttps://doi.org/10.2174/1871520620666200423081235
dc.identifier.urihttps://hdl.handle.net/11454/62884
dc.identifier.volume20en_US
dc.identifier.wosWOS:000573095600002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofAnti-Cancer Agents in Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetforminen_US
dc.subjectsolid lipid nanoparticleen_US
dc.subjecttechnetium tricarbonyl coreen_US
dc.subjectcell cultureen_US
dc.subjectdiabetesen_US
dc.subjectradiolabeleden_US
dc.subjectcanceren_US
dc.titleBiocompatible Delivery System for Metformin: Characterization, Radiolabeling and in Vitro Studiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu